NasdaqCM:NYMX

Stock Analysis Report

Executive Summary

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population.

Snowflake

Fundamentals

Flawless balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Nymox Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-8.7%

NYMX

1.6%

US Biotechs

0.4%

US Market


1 Year Return

5.3%

NYMX

-7.7%

US Biotechs

6.9%

US Market

Return vs Industry: NYMX exceeded the US Biotechs industry which returned -7.7% over the past year.

Return vs Market: NYMX underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

NYMXIndustryMarket
7 Day-8.7%1.6%0.4%
30 Day-10.6%-2.4%-1.2%
90 Day9.9%-1.5%-0.4%
1 Year5.3%5.3%-6.9%-7.7%9.3%6.9%
3 Year-45.7%-45.7%14.7%10.7%45.8%36.4%
5 Year-64.6%-64.6%-2.3%-7.0%62.9%45.1%

Price Volatility Vs. Market

How volatile is Nymox Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Nymox Pharmaceutical undervalued compared to its fair value and its price relative to the market?

16.4x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate NYMX's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate NYMX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NYMX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: NYMX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate NYMX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NYMX is overvalued based on its PB Ratio (16.4x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Nymox Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nymox Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Nymox Pharmaceutical performed over the past 5 years?

-9.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: NYMX is unprofitable, and losses have increased over the past 5 years at a rate of -9.9% per year.

Accelerating Growth: Unable to compare NYMX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NYMX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: NYMX has a negative Return on Equity (-178.78%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: NYMX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: NYMX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Nymox Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: NYMX's short term assets ($9.2M) exceeds its short term liabilities ($1.7M)

Long Term Liabilities: NYMX's short term assets (9.2M) exceeds its long term liabilities (238.0K)


Debt to Equity History and Analysis

Debt Level: NYMX is debt free.

Reducing Debt: NYMX had no debt 5 years ago.


Balance Sheet

Inventory Level: NYMX has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if NYMX's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NYMX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NYMX has sufficient cash runway for 1.144823 years if free cash flow continues to reduce at historical rates of -23.7% each year.


Next Steps

Dividend

What is Nymox Pharmaceutical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate NYMX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NYMX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if NYMX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NYMX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NYMX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Nymox Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

13.3yrs

Average board tenure


CEO

Paul Averback (68yo)

0yrs

Tenure

US$3,499,991

Compensation

Dr. Paul Averback, M.D., D A.B.P., has been the President of Nymox Pharmaceutical Corporation since September 1995 and serves as its Chief Executive Officer. Dr. Averback is the Founder of Nymox Pharmaceut ...


CEO Compensation Analysis

Compensation vs. Market: Paul's total compensation ($USD3.50M) is about average for companies of similar size in the US market ($USD491.38K).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.


Board Age and Tenure

13.3yrs

Average Tenure

62yo

Average Age

Experienced Board: NYMX's board of directors are seasoned and experienced ( 13.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$12,10412 Jul 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares7,000
Max PriceUS$1.73
BuyUS$11,40010 Jul 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares7,000
Max PriceUS$1.63
BuyUS$13,04909 Jul 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares9,000
Max PriceUS$1.45
BuyUS$12,35403 Jul 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares8,000
Max PriceUS$1.54
BuyUS$12,30502 Jul 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares9,000
Max PriceUS$1.37
BuyUS$14,94801 Jul 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares10,000
Max PriceUS$1.52
BuyUS$14,02328 Jun 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares9,000
Max PriceUS$1.56
BuyUS$13,68027 Jun 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares8,000
Max PriceUS$1.71
BuyUS$15,53326 Jun 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares9,000
Max PriceUS$1.73
BuyUS$15,91821 Jun 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares9,000
Max PriceUS$1.77
BuyUS$13,52920 Jun 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares8,000
Max PriceUS$1.69
BuyUS$15,04619 Jun 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares9,000
Max PriceUS$1.67
BuyUS$11,34418 Jun 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares8,000
Max PriceUS$1.42
BuyUS$45912 Jun 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares287
Max PriceUS$1.60
BuyUS$24,97812 Jun 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares16,713
Max PriceUS$1.54
BuyUS$15,64807 Jun 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares10,000
Max PriceUS$1.59
BuyUS$17,09306 Jun 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares11,000
Max PriceUS$1.56
BuyUS$30,52304 Jun 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares19,000
Max PriceUS$1.62
BuyUS$14,96731 May 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares8,500
Max PriceUS$1.77
BuyUS$15,09830 May 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares9,000
Max PriceUS$1.68
BuyUS$24,40628 May 19
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares15,500
Max PriceUS$1.59
BuyUS$15,79603 Jan 19
Erik Danielsen
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares11,000
Max PriceUS$1.54
BuyUS$9,00714 Dec 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares5,237
Max PriceUS$1.72
BuyUS$10,28513 Dec 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares6,000
Max PriceUS$1.71
BuyUS$8,35912 Dec 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares5,000
Max PriceUS$1.67
BuyUS$12,13211 Dec 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares7,500
Max PriceUS$1.62
BuyUS$11,82110 Dec 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares7,000
Max PriceUS$1.69
BuyUS$2,43607 Dec 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,400
Max PriceUS$1.74
BuyUS$12,89906 Dec 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares7,500
Max PriceUS$1.72
BuyUS$9,20003 Dec 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares5,000
Max PriceUS$1.84
BuyUS$12,66030 Nov 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares7,000
Max PriceUS$1.81
BuyUS$13,67928 Nov 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares8,000
Max PriceUS$1.71
BuyUS$37,96121 Nov 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares21,000
Max PriceUS$1.93
BuyUS$13,99415 Nov 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares7,000
Max PriceUS$2.00
BuyUS$27,22513 Nov 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares13,000
Max PriceUS$2.14
BuyUS$74009 Nov 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares363
Max PriceUS$2.04
SellUS$4,394,00006 Nov 18
Paul Averback
EntityIndividual
Role
Chief Executive Officer
Founder
Shares1,787,600
Max PriceUS$2.50
BuyUS$4,98806 Nov 18
Randall Lanham
EntityIndividual
Role
Member of the Board of Directors
General Counsel
Shares2,900
Max PriceUS$1.72
BuyUS$13,84206 Nov 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares7,000
Max PriceUS$1.98
BuyUS$11,40002 Nov 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares6,000
Max PriceUS$1.90
BuyUS$32,16401 Nov 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares18,000
Max PriceUS$1.79
BuyUS$16,22526 Oct 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares10,000
Max PriceUS$1.63
BuyUS$13,34025 Oct 18
James Robinson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares8,000
Max PriceUS$1.67

Ownership Breakdown


Management Team

  • Paul Averback (68yo)

    Founder

    • Tenure: 0yrs
    • Compensation: US$3.50m
  • Randall Lanham (55yo)

    General Counsel

    • Tenure: 13.3yrs
    • Compensation: US$537.37k
  • Erik Danielsen (56yo)

    Chief Financial Officer

    • Tenure: 4.3yrs
    • Compensation: US$442.50k

Board Members

  • Paul Averback (68yo)

    Founder

    • Tenure: 0yrs
    • Compensation: US$3.50m
  • Rich Cutler (61yo)

    Lead Independent Director

    • Tenure: 0yrs
    • Compensation: US$4.50k
  • David Morse (62yo)

    Independent Director

    • Tenure: 13.3yrs
    • Compensation: US$4.50k
  • Randall Lanham (55yo)

    General Counsel

    • Tenure: 13.3yrs
    • Compensation: US$537.37k
  • James Robinson (84yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: US$4.50k

Company Information

Nymox Pharmaceutical Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nymox Pharmaceutical Corporation
  • Ticker: NYMX
  • Exchange: NasdaqCM
  • Founded: 1989
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$124.098m
  • Shares outstanding: 69.72m
  • Website: https://www.nymox.com

Location

  • Nymox Pharmaceutical Corporation
  • Bay & Deveaux Streets
  • 2nd Floor
  • Nassau
  • Bahamas

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NYMXNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDNov 1997
NYMDB (Deutsche Boerse AG)YesCommon SharesDEEURNov 1997

Biography

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or sa ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 23:38
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.